Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib and TACE for HCC recurrence prevention
NCT03838796Unknown
- Sponsor
- Fudan University
- Start
- Jan 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Fudan University. Primary endpoint: Disease-Free Survival at 2 years. Status: unknown.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03838796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838796.